Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-08-05

AUTHORS

Hirohisa Nakamae

ABSTRACT

The successful application of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) led to the expansion of its application to HLA-matched related and unrelated allo-HCT. Notably, single-agent PTCy was found to be feasible for GVHD prevention in HLA-matched bone marrow transplantation. Single-agent PTCy prophylaxis was later attempted to control GVHD in HLA-matched peripheral blood stem cell transplantation (PBSCT), but this approach was inadequate to alleviate GVHD as evidenced by the high incidence of severe GVHD and/or non-relapse mortality. Therefore, various combinations of immunosuppressants with PTCy have been explored to identify the optimal drug combination that would efficiently prevent GVHD in HLA-matched PBSCT. A recent murine study helped clarify the putative mechanism underlying the activity of PTCy, demonstrating that PTCy impairs the proliferation and function of alloreactive T cells from the donor, but does not eliminate alloreactive T cells altogether. In addition, imbalanced reconstitution of NK cell as well as T cells has been observed in HLA-haploidentical allo-HCT. Therefore, it remains unclear whether or not PTCy-containing GVHD prophylaxis should replace the classical GVHD prophylaxis regimen in the HLA-matched setting, and convincing evidence supporting the benefits of PTCy is needed. More... »

PAGES

465-481

References to SciGraph publications

  • 2019-10-24. Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases in BONE MARROW TRANSPLANTATION
  • 2020-11-02. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation in ANNALS OF HEMATOLOGY
  • 2020-12-01. Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study in BONE MARROW TRANSPLANTATION
  • 2020-06-10. Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study in FRONTIERS OF MEDICINE
  • 2020-05-14. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia in LEUKEMIA
  • 2018-03-15. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2019-03-26. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study in ANNALS OF HEMATOLOGY
  • 2021-05-28. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2020-07-03. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2021-09-29. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2020-05-06. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2022-01-25. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT in BONE MARROW TRANSPLANTATION
  • 2021-05-03. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2019-12-10. Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature in BONE MARROW TRANSPLANTATION
  • 2018-10-18. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation in BONE MARROW TRANSPLANTATION
  • 2007-03-12. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells in BONE MARROW TRANSPLANTATION
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12185-022-03428-3

    DOI

    http://dx.doi.org/10.1007/s12185-022-03428-3

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1150023820

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35930118


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cyclophosphamide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Graft vs Host Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematopoietic Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunosuppressive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peripheral Blood Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Hematology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Hematology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakamae", 
            "givenName": "Hirohisa", 
            "id": "sg:person.01014223462.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/s13045-020-00923-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128975294", 
              "https://doi.org/10.1186/s13045-020-00923-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-019-0771-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123238094", 
              "https://doi.org/10.1038/s41409-019-0771-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-021-01094-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138446164", 
              "https://doi.org/10.1186/s13045-021-01094-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-019-0725-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1122089181", 
              "https://doi.org/10.1038/s41409-019-0725-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-020-04317-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132263276", 
              "https://doi.org/10.1007/s00277-020-04317-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-019-03673-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113006358", 
              "https://doi.org/10.1007/s00277-019-03673-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-022-01577-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1144967958", 
              "https://doi.org/10.1038/s41409-022-01577-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-018-0367-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107682611", 
              "https://doi.org/10.1038/s41409-018-0367-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11684-019-0730-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128391121", 
              "https://doi.org/10.1007/s11684-019-0730-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-020-00882-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127423966", 
              "https://doi.org/10.1186/s13045-020-00882-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-020-0863-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127594828", 
              "https://doi.org/10.1038/s41375-020-0863-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-021-03228-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141488876", 
              "https://doi.org/10.1007/s12185-021-03228-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-021-01086-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1137716966", 
              "https://doi.org/10.1186/s13045-021-01086-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1705628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030223904", 
              "https://doi.org/10.1038/sj.bmt.1705628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-020-01144-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132996672", 
              "https://doi.org/10.1038/s41409-020-01144-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-018-0586-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101548957", 
              "https://doi.org/10.1186/s13045-018-0586-4"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-08-05", 
        "datePublishedReg": "2022-08-05", 
        "description": "The successful application of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) led to the expansion of its application to HLA-matched related and unrelated allo-HCT. Notably, single-agent PTCy was found to be feasible for GVHD prevention in HLA-matched bone marrow transplantation. Single-agent PTCy prophylaxis was later attempted to control GVHD in HLA-matched peripheral blood stem cell transplantation (PBSCT), but this approach was inadequate to alleviate GVHD as evidenced by the high incidence of severe GVHD and/or non-relapse mortality. Therefore, various combinations of immunosuppressants with PTCy have been explored to identify the optimal drug combination that would efficiently prevent GVHD in HLA-matched PBSCT. A recent murine study helped clarify the putative mechanism underlying the activity of PTCy, demonstrating that PTCy impairs the proliferation and function of alloreactive T cells from the donor, but does not eliminate alloreactive T cells altogether. In addition, imbalanced reconstitution of NK cell as well as T cells has been observed in HLA-haploidentical allo-HCT. Therefore, it remains unclear whether or not PTCy-containing GVHD prophylaxis should replace the classical GVHD prophylaxis regimen in the HLA-matched setting, and convincing evidence supporting the benefits of PTCy is needed.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12185-022-03428-3", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.6834544", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1076985", 
            "issn": [
              "0925-5710", 
              "1865-3774"
            ], 
            "name": "International Journal of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "116"
          }
        ], 
        "keywords": [
          "peripheral blood stem cell transplantation", 
          "post-transplantation cyclophosphamide", 
          "allogeneic hematopoietic cell transplantation", 
          "hematopoietic cell transplantation", 
          "alloreactive T cells", 
          "cell transplantation", 
          "T cells", 
          "blood stem cell transplantation", 
          "host disease (GVHD) prophylaxis", 
          "non-relapse mortality", 
          "combination of immunosuppressants", 
          "GVHD prophylaxis regimen", 
          "stem cell transplantation", 
          "bone marrow transplantation", 
          "recent murine studies", 
          "optimal drug combinations", 
          "allo-HCT", 
          "GVHD prevention", 
          "severe GVHD", 
          "GVHD prophylaxis", 
          "prophylaxis regimen", 
          "disease prophylaxis", 
          "NK cells", 
          "marrow transplantation", 
          "murine studies", 
          "GVHD", 
          "drug combinations", 
          "high incidence", 
          "HLA", 
          "transplantation", 
          "prophylaxis", 
          "putative mechanisms", 
          "cyclophosphamide", 
          "cells", 
          "regimen", 
          "immunosuppressants", 
          "graft", 
          "mortality", 
          "incidence", 
          "Hct", 
          "systematic overview", 
          "prevention", 
          "allo", 
          "impairs", 
          "proliferation", 
          "donors", 
          "setting", 
          "reconstitution", 
          "combination", 
          "evidence", 
          "activity", 
          "study", 
          "benefits", 
          "mechanism", 
          "function", 
          "addition", 
          "overview", 
          "successful application", 
          "approach", 
          "expansion", 
          "applications"
        ], 
        "name": "Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide", 
        "pagination": "465-481", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1150023820"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12185-022-03428-3"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35930118"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12185-022-03428-3", 
          "https://app.dimensions.ai/details/publication/pub.1150023820"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:08", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_920.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12185-022-03428-3"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-022-03428-3'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-022-03428-3'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-022-03428-3'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-022-03428-3'


     

    This table displays all metadata directly associated to this object as RDF triples.

    220 TRIPLES      21 PREDICATES      110 URIs      86 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12185-022-03428-3 schema:about N132266d1a0d1451f88d67a2f97bde3b4
    2 N7b4570f928254ea3b17a6a3bcaa8de34
    3 N82d2115c9a634883b7ae9a2e0385af37
    4 N85dc7af28f50456f8e156fbcc40ac718
    5 N8842acf580a541eb8e39a190b735b04e
    6 N989ba92ff7594b31958300cdfc6cb5ac
    7 Nbe083fd9beb248c09254a6c605443953
    8 Ndc23915af74648a5850aa87c7464f3bd
    9 anzsrc-for:11
    10 anzsrc-for:1102
    11 schema:author Ne58ba94b1c604258b5cc63cc3368ca28
    12 schema:citation sg:pub.10.1007/s00277-019-03673-3
    13 sg:pub.10.1007/s00277-020-04317-7
    14 sg:pub.10.1007/s11684-019-0730-8
    15 sg:pub.10.1007/s12185-021-03228-1
    16 sg:pub.10.1038/s41375-020-0863-4
    17 sg:pub.10.1038/s41409-018-0367-2
    18 sg:pub.10.1038/s41409-019-0725-8
    19 sg:pub.10.1038/s41409-019-0771-2
    20 sg:pub.10.1038/s41409-020-01144-2
    21 sg:pub.10.1038/s41409-022-01577-x
    22 sg:pub.10.1038/sj.bmt.1705628
    23 sg:pub.10.1186/s13045-018-0586-4
    24 sg:pub.10.1186/s13045-020-00882-6
    25 sg:pub.10.1186/s13045-020-00923-0
    26 sg:pub.10.1186/s13045-021-01086-2
    27 sg:pub.10.1186/s13045-021-01094-2
    28 schema:datePublished 2022-08-05
    29 schema:datePublishedReg 2022-08-05
    30 schema:description The successful application of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) led to the expansion of its application to HLA-matched related and unrelated allo-HCT. Notably, single-agent PTCy was found to be feasible for GVHD prevention in HLA-matched bone marrow transplantation. Single-agent PTCy prophylaxis was later attempted to control GVHD in HLA-matched peripheral blood stem cell transplantation (PBSCT), but this approach was inadequate to alleviate GVHD as evidenced by the high incidence of severe GVHD and/or non-relapse mortality. Therefore, various combinations of immunosuppressants with PTCy have been explored to identify the optimal drug combination that would efficiently prevent GVHD in HLA-matched PBSCT. A recent murine study helped clarify the putative mechanism underlying the activity of PTCy, demonstrating that PTCy impairs the proliferation and function of alloreactive T cells from the donor, but does not eliminate alloreactive T cells altogether. In addition, imbalanced reconstitution of NK cell as well as T cells has been observed in HLA-haploidentical allo-HCT. Therefore, it remains unclear whether or not PTCy-containing GVHD prophylaxis should replace the classical GVHD prophylaxis regimen in the HLA-matched setting, and convincing evidence supporting the benefits of PTCy is needed.
    31 schema:genre article
    32 schema:isAccessibleForFree false
    33 schema:isPartOf N66b7395aa489493687bf0789224c228e
    34 Nbc170d4bccec4a3eb90eec6feda0f412
    35 sg:journal.1076985
    36 schema:keywords GVHD
    37 GVHD prevention
    38 GVHD prophylaxis
    39 GVHD prophylaxis regimen
    40 HLA
    41 Hct
    42 NK cells
    43 T cells
    44 activity
    45 addition
    46 allo
    47 allo-HCT
    48 allogeneic hematopoietic cell transplantation
    49 alloreactive T cells
    50 applications
    51 approach
    52 benefits
    53 blood stem cell transplantation
    54 bone marrow transplantation
    55 cell transplantation
    56 cells
    57 combination
    58 combination of immunosuppressants
    59 cyclophosphamide
    60 disease prophylaxis
    61 donors
    62 drug combinations
    63 evidence
    64 expansion
    65 function
    66 graft
    67 hematopoietic cell transplantation
    68 high incidence
    69 host disease (GVHD) prophylaxis
    70 immunosuppressants
    71 impairs
    72 incidence
    73 marrow transplantation
    74 mechanism
    75 mortality
    76 murine studies
    77 non-relapse mortality
    78 optimal drug combinations
    79 overview
    80 peripheral blood stem cell transplantation
    81 post-transplantation cyclophosphamide
    82 prevention
    83 proliferation
    84 prophylaxis
    85 prophylaxis regimen
    86 putative mechanisms
    87 recent murine studies
    88 reconstitution
    89 regimen
    90 setting
    91 severe GVHD
    92 stem cell transplantation
    93 study
    94 successful application
    95 systematic overview
    96 transplantation
    97 schema:name Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide
    98 schema:pagination 465-481
    99 schema:productId N26ba1d523812422faec8417df9c52739
    100 N2b2d07b26a3446e883f5f0528171127f
    101 N519ec4c757c44eaaae054713cbe1a8b8
    102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1150023820
    103 https://doi.org/10.1007/s12185-022-03428-3
    104 schema:sdDatePublished 2022-11-24T21:08
    105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    106 schema:sdPublisher Nebca0b727705497782668e0760fdc8d8
    107 schema:url https://doi.org/10.1007/s12185-022-03428-3
    108 sgo:license sg:explorer/license/
    109 sgo:sdDataset articles
    110 rdf:type schema:ScholarlyArticle
    111 N132266d1a0d1451f88d67a2f97bde3b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Hematopoietic Stem Cell Transplantation
    113 rdf:type schema:DefinedTerm
    114 N26ba1d523812422faec8417df9c52739 schema:name doi
    115 schema:value 10.1007/s12185-022-03428-3
    116 rdf:type schema:PropertyValue
    117 N2b2d07b26a3446e883f5f0528171127f schema:name dimensions_id
    118 schema:value pub.1150023820
    119 rdf:type schema:PropertyValue
    120 N519ec4c757c44eaaae054713cbe1a8b8 schema:name pubmed_id
    121 schema:value 35930118
    122 rdf:type schema:PropertyValue
    123 N66b7395aa489493687bf0789224c228e schema:issueNumber 4
    124 rdf:type schema:PublicationIssue
    125 N7b4570f928254ea3b17a6a3bcaa8de34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Immunosuppressive Agents
    127 rdf:type schema:DefinedTerm
    128 N82d2115c9a634883b7ae9a2e0385af37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Graft vs Host Disease
    130 rdf:type schema:DefinedTerm
    131 N85dc7af28f50456f8e156fbcc40ac718 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Cyclophosphamide
    133 rdf:type schema:DefinedTerm
    134 N8842acf580a541eb8e39a190b735b04e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Animals
    136 rdf:type schema:DefinedTerm
    137 N989ba92ff7594b31958300cdfc6cb5ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Mice
    139 rdf:type schema:DefinedTerm
    140 Nbc170d4bccec4a3eb90eec6feda0f412 schema:volumeNumber 116
    141 rdf:type schema:PublicationVolume
    142 Nbe083fd9beb248c09254a6c605443953 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Humans
    144 rdf:type schema:DefinedTerm
    145 Ndc23915af74648a5850aa87c7464f3bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Peripheral Blood Stem Cell Transplantation
    147 rdf:type schema:DefinedTerm
    148 Ne58ba94b1c604258b5cc63cc3368ca28 rdf:first sg:person.01014223462.98
    149 rdf:rest rdf:nil
    150 Nebca0b727705497782668e0760fdc8d8 schema:name Springer Nature - SN SciGraph project
    151 rdf:type schema:Organization
    152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Medical and Health Sciences
    154 rdf:type schema:DefinedTerm
    155 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Cardiorespiratory Medicine and Haematology
    157 rdf:type schema:DefinedTerm
    158 sg:grant.6834544 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-022-03428-3
    159 rdf:type schema:MonetaryGrant
    160 sg:journal.1076985 schema:issn 0925-5710
    161 1865-3774
    162 schema:name International Journal of Hematology
    163 schema:publisher Springer Nature
    164 rdf:type schema:Periodical
    165 sg:person.01014223462.98 schema:affiliation grid-institutes:None
    166 schema:familyName Nakamae
    167 schema:givenName Hirohisa
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98
    169 rdf:type schema:Person
    170 sg:pub.10.1007/s00277-019-03673-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113006358
    171 https://doi.org/10.1007/s00277-019-03673-3
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1007/s00277-020-04317-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132263276
    174 https://doi.org/10.1007/s00277-020-04317-7
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1007/s11684-019-0730-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128391121
    177 https://doi.org/10.1007/s11684-019-0730-8
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/s12185-021-03228-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141488876
    180 https://doi.org/10.1007/s12185-021-03228-1
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1038/s41375-020-0863-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127594828
    183 https://doi.org/10.1038/s41375-020-0863-4
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/s41409-018-0367-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107682611
    186 https://doi.org/10.1038/s41409-018-0367-2
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1038/s41409-019-0725-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122089181
    189 https://doi.org/10.1038/s41409-019-0725-8
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1038/s41409-019-0771-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123238094
    192 https://doi.org/10.1038/s41409-019-0771-2
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1038/s41409-020-01144-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132996672
    195 https://doi.org/10.1038/s41409-020-01144-2
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/s41409-022-01577-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1144967958
    198 https://doi.org/10.1038/s41409-022-01577-x
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1038/sj.bmt.1705628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030223904
    201 https://doi.org/10.1038/sj.bmt.1705628
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1186/s13045-018-0586-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101548957
    204 https://doi.org/10.1186/s13045-018-0586-4
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1186/s13045-020-00882-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127423966
    207 https://doi.org/10.1186/s13045-020-00882-6
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1186/s13045-020-00923-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128975294
    210 https://doi.org/10.1186/s13045-020-00923-0
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1186/s13045-021-01086-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137716966
    213 https://doi.org/10.1186/s13045-021-01086-2
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1186/s13045-021-01094-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138446164
    216 https://doi.org/10.1186/s13045-021-01094-2
    217 rdf:type schema:CreativeWork
    218 grid-institutes:None schema:alternateName Hematology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan
    219 schema:name Hematology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan
    220 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...